Kauffman Michael
- SEC CIK
- 0001364719
In the past year, 1 open-market sale filing worth $85.5K and no purchases.
Current role at each company
- KYNB Kyntra Bio, Inc.Directoras of Jun 17, 2026
- KZR Kezar Life Sciences, Inc.Directoras of May 11, 2026
- VSTM Verastem, Inc.President of Developmentas of Jan 8, 2026
- ACET Adicet Bio, Inc.Directoras of Aug 23, 2024
- KPTI Karyopharm Therapeutics Inc.Directoras of Mar 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $85.5K
- 1 filing
- Net
- −$85.5K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Kauffman Michael as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VSTM Verastem, Inc.
President of Development1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 (view filing) | Nov 21 | 4 days | Kauffman MichaelDirector | SSale | −8.55K | $10.00 | −$85.5K | −49.7%8.67K after | 10b5-1 |
ACET Adicet Bio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Kauffman MichaelDirector | SSale | −5.90K | $1.43 | −$8.44K | −50.0%5.90K after |
KPTI Karyopharm Therapeutics Inc.
Director6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Kauffman MichaelDirector | SSale | −6.76K | $9.86 | −$66.7K | −0.9%708.1K after | Duplicate filing |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Kauffman MichaelDirector | SSale | −6.71K | $9.86 | −$66.1K | −0.7%913.4K after | Duplicate filing |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Kauffman MichaelDirector | SSale | −9.08K | $12.12 | −$110.0K | −1.3%699.0K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Kauffman MichaelDirector | SSale | −9.09K | $12.12 | −$110.1K | −1.0%904.4K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Kauffman MichaelDirector | SSale | −6.23K | $10.24 | −$63.8K | −0.9%713.8K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Kauffman MichaelDirector | SSale | −6.23K | $10.24 | −$63.8K | −0.7%898.1K after |
KZR Kezar Life Sciences, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Kauffman MichaelDirector | SSale | −5.00K | $16.45 | −$82.3K | −7.3%63.7K after |